Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorolac + bupivacaine is a combination of two drugs used primarily for perioperative and postoperative pain management. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties, while bupivacaine is an amide-type local anesthetic that blocks nerve impulse conduction by inhibiting voltage-gated sodium channels. The combination leverages the rapid-onset local anesthesia of bupivacaine with the prolonged analgesic effect of ketorolac to provide enhanced pain relief after surgical procedures. Clinical studies have shown that this combination reduces postoperative pain scores, prolongs the duration of analgesia, decreases opioid requirements, and can be safely administered via various routes such as intra-articular or intraperitoneal injection[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + bupivacaine.